Blue Matter Blog

Central Nervous System Therapies: A Look at Rising Investment Activity
December 15, 2020

In Part 1 of this series, we said that a “quiet revolution” has been taking place in central nervous system (CNS) therapies.  While much attention has been focused on the dramatic advancements in oncology, companies large and small have been focusing more resources on CNS research, and the pace of advancement is accelerating.  In that …

Success in Rare Diseases, Part IV: Successfully Implementing Clinical Programs in the Rare Disease Ecosystem
December 8, 2020

In the first three parts of our series, we introduced the rare disease (RD) ecosystem and its interconnected stakeholders. We also discussed the challenges and key considerations for RD clinical trial design – both (pre)registrational as well as ongoing evidence generation after the first approval. Here, we examine the practical considerations of successful clinical trial …